KRAS and lung carcinoma: Approximately 25% of lung adenocarcinomas, a dominant form of lung cancer harbor oncogenic KRAS mutations, and this poses a significant therapeutic challenge, as KRAS mutations are generally associated with poor prognosis and resistance to chemotherapy [2, 3].